Press Enter to search · Esc to close
Nephrologists are floating a new diagnostic umbrella — Metabolic Kidney Disease — to catch the quiet damage that obesity, insulin resistance and fatty liver inflict on kidneys years before standard tests flag a problem.
A wave of 2025 analyses is dissecting the real mechanisms behind the headline weight loss — and the picture is messier, smarter, and more interesting than the marketing.
A common gut bacterium called Blautia wexlerae appears to rewrite dietary fats into signals that nudge GLP-1 release. The science is early — but the mechanism is genuinely new.
A Riyadh case-control study paired with a fresh meta-analysis sharpens the dietary case against fast food in inflammatory bowel disease — and gives busy men a concrete lever to pull.
A new mediation analysis points to E-selectin, a marker of blood-vessel stress, as a quiet link between metabolic risk and insulin resistance — while CRP, the inflammation test most of us know, came up short.
The disease formerly known as fatty liver got a new name in 2023 — and a fresh acknowledgment that it rarely travels alone. Here's what the latest review tells us about the liver-kidney link.
A new gene-metabolite map suggests incretin-pathway drugs act on a web of cardiovascular and metabolic systems — not just glucose. Here's what that means for patients in 2026.
A long-running Japanese cohort and a fresh Indian prevalence study complicate the metabolic-syndrome story — pointing to the components that actually move the mortality needle.
New research is beginning to explain why GLP-1 drugs work brilliantly for some and modestly for others — and what comes after the first generation of blockbusters.
A new meta-analysis pooling seven direct comparisons gives us the cleanest apples-to-apples read yet on how the two big incretin drugs stack up for weight loss.